The Rebate Rule: US Pricing Proposal Becomes Congressional Piggy Bank
Executive Summary
A policy eliminating rebates in the Medicare Part D program will be delayed until Jan. 1, 2026 – and is very likely to be repealed altogether. If that staves off more draconian reforms, the biopharma industry will celebrate.
You may also be interested in...
Back To The Well: Rebate Reform Rule Delay Would Fund Senate Gun Control Bill Provisions
For biopharma manufacturers, chipping away at the rebate rule is a relatively painless drug pricing “pay for” compared to price control policies.
OIG Still Wary Of Anti-Kickback Safe Harbors For Value-Based Arrangements Involving Drugs
US health department’s Office of Inspector General reviews its concerns with allowing remuneration from drug firms in value-based arrangements in latest report to Congress.
US Employers Say Government Drug Pricing Reforms Needed To Supplement Market-Based Efforts
Annual Business Group on Health survey on employer-sponsored insurance covers pricing reform, rebate model alternatives, paying for high-cost drugs and copay coupons.